US EditionMounjaro leads to significantly more weight loss than Ozempic, study suggests
49 Articles
49 Articles
Pacienții care au primit Mounjaro au fost „mai susceptibili de a obține o pierdere în greutate de 5%, 10% sau 15% sau mai mult”, comparativ cu cei care au primit Ozempic, potrivit studiului publicat luni în revista JAMA. Iar acești pacienți care au primit Mounjaro „au înregistrat reduceri mai mari de greutate la 3, 6 și 12 luni”, adaugă studiul. În detaliu, pacienții care au primit Mounjaro au pierdut, de exemplu, în medie aproximativ 15% din gr…
Zepbound outperforms Ozempic and Wegovy in head-to-head weight loss study
Tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, leads to more weight loss than semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, new research suggests.
Truveta's real-world data study comparing tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss published in JAMA Internal Medicine
BELLEVUE, Wash., July 08, 2024 (GLOBE NEWSWIRE) -- Today Truveta announced that its comparative effectiveness study exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro) has been published in JAMA Internal Medicine. Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, are used to trea…
Most patients managed to lose 5% or more in weight after one year, but those who took the former were more likely to lose weight and achieved greater weight loss Patients who took the new drug Mounjaro, from Eli Lilly, achieved significantly greater weight loss than those who took Ozempic, from Novo Nordisk, a comparative study published this Monday showed. Researchers analyzed the electronic health records of more than 18,000 patients from the …
Novo Nordisk's biggest competitor in the diabetes and weight loss market, the US pharmaceutical giant Eli Lilly, has in...
Coverage Details
Bias Distribution
- 87% of the sources are Center
To view factuality data please Upgrade to Premium
